Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-126 Gel PK and Safety Study in Acne Vulgaris
NCT03653403Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clindamycin phosphate + adapalene + benzoyl peroxide in acne vulgaris (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Day 28. Started Aug 2018; status: completed.
02
Drugs
clindamycin phosphate + adapalene + benzoyl peroxide
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03653403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03653403.